About A3P Biomedical

A3P Biomedical is a Swedish medical technology company developing solutions to improve the diagnosis of prostate cancer.

The company is particularly known for its innovative test, Stockholm3, which offers a more advanced alternative to traditional PSA tests.

The Stockholm3 test combines clinical data, genetic markers and protein biomarkers to provide a more accurate assessment of the risk of aggressive prostate cancer. By improving accuracy, the test can reduce the number of unnecessary biopsies by up to 50 % while identifying twice as many cases of aggressive cancer compared to the PSA test.

Stockholm3 test

Stockholm3 is currently available in several countries, with a strong presence in the Nordic region and selected locations in Europe. In Sweden, the test is offered in both private and public healthcare, including at St. Göran's Prostate Cancer Center, one of the country's leading prostate cancer diagnostic units.

The company is actively working to expand access globally with the goal of establishing Stockholm3 as a standard method for prostate cancer screening in Europe and the US. The goal is to contribute to improved patient care while reducing healthcare costs and unnecessary procedures.

Advantages of Stockholm3 compared to PSA

• Increased accuracy: Reduction of false positives and a more specific risk assessment.
• Previous discovery: The test identifies twice as many cases of aggressive prostate cancer as PSA.
• Fewer unnecessary biopsies: Reduction of up to 50 %, saving resources and reducing patient discomfort.
• More effective care: Reduced costs through better precision and fewer unnecessary interventions.

Researchers from Karolinska Institutet

A3P Biomedical was founded based on research from Karolinska Institutet. Leading researchers such as Henrik Grönberg, Professor of Oncology and internationally recognized expert in prostate cancer, and Tobias Nordström, Associate Professor and specialist in prostate cancer diagnostics, have been central to the development of the Stockholm3 test.

In May 2022, A3P Biomedical completed a directed share issue of SEK 400 MILLION to a number of prominent investors, including Stena Sessan, TomEqt Private AB, Flerie Invest AB, The Baltic Sea Foundation and Inbox Capital. The capital has been used to support the company's growth strategy, including the global expansion of Stockholm3.

How to buy shares in A3P Biomedical

1. Create an account on Eqvor.com
2. Click on the buy button at A3P in the OTC list.
3. Choose how many shares you want to buy and at what price, and to which depository you want the shares delivered.
4. Wait for the order to be matched.
5. Send your settlement note to your bank/securities company.
6. The shares land in your custody - Done!

In addition to A3P Biomedical, we have also helped investors buy and sell shares in other exciting unlisted companies in sectors such as 

Hbiotechnology and bioengineering, there are BioCrine, Doktor.se, MEDS Pharmacy, Sigrid Therapeutics and Mindler. Under financial services there are Klarna, Mynt, Yabie and Billogram.

Within technology and innovation: Dirac Research, Exeger, Cascade Drives, Sana Labs, Quartr and Virtune. I the consumer and lifestyle segment: CDLP, Estrid and Marshall.

Under transport and vehicle technology there are Einride, Voi, XShore, Koenigsegg and Candela. Within energy and sustainability: Blykalla and Svea Solar.

In addition: Epidemic Sound (media), Kaunis Iron (industry),  GreenGold Group (forestry), and investment companies Röko, byWiT and Nicoya.

We can also help to implement deals in other unlisted companies - even if they are not listed on the platform. Contact us if you are looking for a specific case.